ArticleScientific reports2025
Characterization and stability of plasmid DNA calcium nanoparticles using a simple formulation for gene therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gene-based therapy is crucial in treating various disorders and diseases by conferring genetic material to target cells. Calcium phosphate (Ca-P) nanoparticles show promise as a non-viral vector for targeted gene delivery due to cost-effectiveness and established biocompatibility, which enhances their application in nanomedicine. Our previous pre-clinical studies in rats and monkeys exhibited the safety of our Ca-P nanoparticle formulation by local and systemic administration, with a simple preparation. However, the tendency of plasmid DNA-encapsulated Ca-P (pDNA/Ca-P) nanoparticles to aggregate during prolonged storage at inappropriate temperatures is a significant challenge. To investigate the effects of temperature and storage duration on the physicochemical properties and gene delivery efficiency of pDNA/Ca-P nanoparticles, we exposed the pDNA/Ca-P nanoparticles to varied temperatures ranging from − 80 °C to 65 °C for 7 days after formulation and measured physicochemical properties, including size, shape, surface charge, pH level, and pDNA delivery efficiency. The results indicated that pDNA/Ca-P nanoparticles stored at 4 °C and 29 °C exhibited the highest gene expression while maintaining the smallest particle size. Continuous storage at a similar temperature for 5 months demonstrated that the nanoparticles retained their favourable physicochemical properties. These findings showed that the proper long-term storage temperature at 29 °C of the pDNA/Ca-P nanoparticles, without the need for specialised instruments, paves the way for extensive use of Ca-P nanoparticles for gene therapy in pre-clinical and clinical studies in resource-limited areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.